OverviewSuggest Edit

Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
TypePublic
Founded2015
HQWaltham, US
Websitemorphictx.com

Latest Updates

Employees (est.) (Sept 2019)76(+27%)
Revenue (FY, 2019)$3.4 M
Share Price (Nov 2019)$15.9 (-2%)

Morphic Therapeutic Office Locations

Morphic Therapeutic has an office in Waltham
Waltham, US (HQ)
35 Gatehouse Dr
Show all (1)

Morphic Therapeutic Financials and Metrics

Morphic Therapeutic Revenue

Morphic Therapeutic's revenue was reported to be $3.36 m in FY, 2019
USD

Revenue (FY, 2019)

3.4m

Net income (FY, 2019)

(23.8m)

EBIT (FY, 2019)

(24.6m)

Market capitalization (29-Nov-2019)

484.1m

Closing stock price (29-Nov-2019)

15.9

Cash (30-Sept-2019)

159.8m
Morphic Therapeutic's current market capitalization is $484.1 m.
Annual
USDFY, 2017FY, 2019

Revenue

3.4m

General and administrative expense

2.8m5.4m

R&D expense

14.1m22.6m

Operating expense total

16.9m28.0m
Quarterly
USDQ2, 2019Q3, 2019

Revenue

5.6m

General and administrative expense

2.1m2.9m

R&D expense

13.9m12.6m

Operating expense total

16.0m15.5m
Annual
USDFY, 2017FY, 2018

Cash

20.8m185.9m

Prepaid Expenses

479.0k1.2m

Current Assets

21.2m187.1m

PP&E

1.7m1.8m
Quarterly
USDQ2, 2019Q3, 2019

Cash

44.2m159.8m

Accounts Receivable

945.0k2.4m

Prepaid Expenses

1.4m2.9m

Current Assets

172.8m257.0m
Annual
USDFY, 2017FY, 2018

Net Income

(16.9m)(23.8m)

Depreciation and Amortization

434.0k539.0k

Accounts Payable

285.0k862.0k

Cash From Operating Activities

(15.4m)7.6m
Quarterly
USDQ2, 2019Q3, 2019

Net Income

(14.6m)(23.5m)

Depreciation and Amortization

365.0k576.0k

Accounts Payable

1.2m1.5m

Cash From Operating Activities

(13.9m)(27.6m)
USDY, 2019

Revenue/Employee

51.4k

Financial Leverage

1.6 x
Show all financial metrics

Morphic Therapeutic Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Morphic Security Corporation

Morphic Therapeutic Online and Social Media Presence

Embed Graph

Morphic Therapeutic Blogs

Morphic to Present at the Jefferies 2019 London Healthcare Conference

WALTHAM, Mass. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni , M.D., president and chief executive

Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results

MORF-720, α v β 6 -targeted oral integrin inhibitor IND now anticipated in the second half of 2020 α 4 β 7 -targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020 Morphic ends third quarter of 2019 with favorable cash, cash equivalents and marketable securities of $252

Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors

WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Director…

Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen

Deal extends reach of Morphic discovery across all known human integrins Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research Collaboration facilitated by Johnson & Johnson Innovation, Boston WALTHAM, Mass. – February 21, 2019 – Morphi…

Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. – January 2, 2019 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019.

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic The…
Show more

Morphic Therapeutic Frequently Asked Questions

  • When was Morphic Therapeutic founded?

    Morphic Therapeutic was founded in 2015.

  • How many employees does Morphic Therapeutic have?

    Morphic Therapeutic has 76 employees.

  • What is Morphic Therapeutic revenue?

    Latest Morphic Therapeutic annual revenue is $3.4 m.

  • What is Morphic Therapeutic revenue per employee?

    Latest Morphic Therapeutic revenue per employee is $44.2 k.

  • Who are Morphic Therapeutic competitors?

    Competitors of Morphic Therapeutic include Trefoil Therapeutics, Twist Bioscience and KinDex Pharmaceuticals.

  • Where is Morphic Therapeutic headquarters?

    Morphic Therapeutic headquarters is located at 35 Gatehouse Dr, Waltham.

  • Where are Morphic Therapeutic offices?

    Morphic Therapeutic has an office in Waltham.

  • How many offices does Morphic Therapeutic have?

    Morphic Therapeutic has 1 office.